Centogene NV (Centogene NV) Change In Receivables : $9.49 Mil (TTM As of Jun. 2023)

View and export this data going back to 2019. Start your Free Trial

What is Centogene NV Change In Receivables?

Centogene NV's change in receivables for the quarter that ended in Jun. 2023 was $0.00 Mil. It means Centogene NV's Accounts Receivable stayed the same from Dec. 2022 to Jun. 2023 .

Centogene NV's change in receivables for the fiscal year that ended in Dec. 2022 was $7.32 Mil. It means Centogene NV's Accounts Receivable declined by $7.32 Mil from Dec. 2021 to Dec. 2022 .

Centogene NV's Accounts Receivable for the quarter that ended in Jun. 2023 was $19.41 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Centogene NV's liquidation value for the three months ended in Jun. 2023 was $-63.33 Mil.

Centogene NV Change In Receivables Historical Data

The historical data trend for Centogene NV's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Centogene NV Change In Receivables Chart

Centogene NV Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Change In Receivables

Get a 7-Day Free Trial

-5.35

-7.16

-19.67

5.49

7.32

Centogene NV Quarterly Data
	Dec17	Jun18	Sep18	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Dec22	Jun23
Change In Receivables	Get a 7-Day Free Trial															-10.46	3.38	6.11	-	-

Centogene NV Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was $9.49 Mil.

Centogene NV (NAS:CNTG) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Centogene NV's Days Sales Outstanding for the quarter that ended in Jun. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	19.414	/	0	*	91
=

2. In Ben Graham's calculation of liquidation value, Centogene NV's accounts receivable are only considered to be worth 75% of book value:

Centogene NV's liquidation value for the quarter that ended in Jun. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	15.334	-	94.381	+	0.75 * 19.414	+	0.5 * 2.307
=	-63.33

Centogene NV Change In Receivables Related Terms

Thank you for viewing the detailed overview of Centogene NV's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Centogene NV (Centogene NV) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Centogene NV (NAS:CNTG) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

39K:Germany

Address

Am Strande 7, Rostock, MV, DEU, 18055

Website

https://www.centogene.com

Centogene NV is a United States-based company focused on transforming clinical and genetic data into actionable information for patients, physicians, and pharmaceutical companies. The company operates in three segments: pharmaceutical, diagnostics, and COVID-19. Its pharmaceutical segment provides a variety of services to its pharmaceutical partners, including early patient recruitment and identification, epidemiological insights, biomarker discovery, and patient monitoring. Its clinical diagnostics segment provides targeted genetic sequencing and diagnostics services to patients.